Genetically Modified Herpes Virus Shows Promise Against Advanced Melanoma
LOS ANGELES COUNTY, CALIFORNIA, JUL 08 – The engineered herpes virus RP1 combined with nivolumab caused tumor shrinkage or disappearance in one-third of advanced melanoma patients in phase 1-2 trials, FDA review pending.
- At the ASCO meeting in 2025, one-third of advanced melanoma patients treated with RP1 plus nivolumab saw tumor shrinkage, with nearly one-sixth experiencing complete responses.
- Driven by the need for better treatments, the IGNYTE trial involved 140 patients with resistant advanced melanoma, which has a median survival of only a few years.
- Published phase 1-2 data show RP1, combined with nivolumab, reduces tumors beyond injection sites, with results presented at ASCO and published in the Journal of Clinical Oncology, prompting optimism from Dr. In.
- Following the FDA's January 2025 priority review, the phase 3 IGNYTE-3 trial with over 400 participants is now open, advancing RP1's regulatory path.
- Beyond injected tumors, experts predict RP1 will see broader use than T-VEC, the only oncolytic virus approved so far, potentially revolutionizing cancer immunotherapy.
Insights by Ground AI
Does this summary seem wrong?
18 Articles
18 Articles
Genetically modified herpes virus shows promise against advanced melanoma
The herpes simplex virus type 1 (HSV-1), which affects almost two-thirds of the world's population and is generally associated with oral herpes, may cause painful cold sores or fever blisters around the mouth.
·United States
Read Full Article

Cancer-fighting herpes virus shown to be an effective treatment for some advanced melanoma
The herpes simplex virus type 1 (HSV-1), which affects almost two‑thirds of the world's population and is generally associated with oral herpes, may cause painful cold sores or fever blisters around the mouth.


Herpes virus could soon be approved to treat severe skin cancer
A cancer-killing virus could soon be approved for use after shrinking tumours in a third of people with late-stage melanoma
·Baltimore, United States
Read Full ArticleCoverage Details
Total News Sources18
Leaning Left2Leaning Right0Center5Last UpdatedBias Distribution71% Center
Bias Distribution
- 71% of the sources are Center
71% Center
L 29%
C 71%
Factuality
To view factuality data please Upgrade to Premium